Premium
Development of 170 Tm‐DOTA‐cetuximab for radioimmunotherapy
Author(s) -
ShirvaniArani Simindokht,
BahramiSamani Ali,
Jalilian Amir Reza,
ShirvaniArani Amirsaleh,
GhannadiMaragheh Mohammad
Publication year - 2012
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.1957
Subject(s) - chemistry , cetuximab , biodistribution , thulium , dota , radiochemistry , radionuclide therapy , radioimmunotherapy , curium , nuclear chemistry , monoclonal antibody , nuclear medicine , chelation , americium , antibody , medicine , biochemistry , physics , optoelectronics , organic chemistry , doping , immunology , in vitro , biology , plutonium
Thulium‐170 [ T 1/2 = 128.4 days, E β (max) = 968 keV, E γ = 84 keV (3.26%)] has radionuclidic properties suitable for use in therapy. 170 Tm can be produced by a relatively feasible route involving thermal neutron bombardment on natural Tm(NO 3 ) 3 (100% 169 Tm) in medium flux research reactors. The combination of beta‐particle emission of Tm‐170 with therapeutic properties of C225 monoclonal antibody (cetuximab) as well as optimization studies for future Tm‐167 labeling was targeted in this study. Conjugated cetuximab was obtained by the addition of 0.5 ml of a cetuximab pharmaceutical solution (1 mg, in phosphate buffer, pH 7.8) to a glass tube pre‐coated with in situ prepared 1,4,7,10‐tetraazacyclododecane‐ N , N , N , N ‐tetraacetic acid mono‐( N ‐hydroxysuccinimidyl) ester (DOTA‐NHS) (~5 mg) at 25°C. Cetuximab was labeled with 170 Tm‐Thulium chloride (100 MBq) after conjugation with DOTA‐NHS in 2–3 h (radiochemical purity >99%, instant thin‐layer chromatography, specific activity = 77–385 TBq/mmol). Biodistribution studies in wild‐type rats for free Tm‐170 and the radioimmunoconjugate were performed to determine the distribution up to 72 h. A comparative time‐frame study was performed for critical organs for both radiochemical species. The major organs of accumulation were shown to be the lung, liver, and spleen, respectively. Copyright © 2012 John Wiley & Sons, Ltd.